REGIV as a potential biomarker for peritoneal dissemination in gastric adenocarcinoma

Jeong Ho Moon, Yoshiyuki Fujiwara, Yurika Nakamura, Kaoru Okada, Hiroyuki Hanada, Chohei Sakakura, Shuji Takiguchi, Kiyokazu Nakajima, Hiroshi Miyata, Makoto Yamasaki, Yukinori Kurokawa, Masaki Mori, Yuichiro Doki

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

Background This study examined the clinical significance of regenerating islet-derived family member 4 (REGIV) in surgically resected gastric tumors. The potential of REGIV as a biomarker in gastric cancer was also assessed including its predictive value for prognosis and recurrence after surgery. Methods Immunohistochemistry was performed to assess the clinical significance of REGIV expression status in surgically resected specimens. The quantitative genetic diagnostic method, transcription-reverse transcription concerted reaction (TRC) that targeted REGIV mRNA was applied for prediction of peritoneal recurrence in gastric cancer. Results Positive immunostaining for REGIV was observed in 85 cases (52.5%), and correlated significantly with diffuse type histopathology (P = 0.001), advanced T stage (P = 0.022), and frequent peritoneal recurrence (P = 0.009). Multivariate analysis identified advanced T stage (P < 0.001) and REGIV expression (P = 0.034) as independent prognostic factors for peritoneal recurrence-free survival. Overexpression of REGIV protein was evident in the majority of peritoneal tumors (93.8%). REGIV mRNA assessed by TRC could be a predictive marker for peritoneal recurrence after curative operation. Conclusions REGIV overexpression is common in primary gastric tumors and a potentially suitable marker of diffuse type histopathology and peritoneal dissemination. Overexpression of REGIV mRNA, assessed by the TRC method, is a potentially suitable marker of peritoneal recurrence after curative resection.

Original languageEnglish
Pages (from-to)189-194
Number of pages6
JournalJournal of Surgical Oncology
Volume105
Issue number2
DOIs
Publication statusPublished - Feb 1 2012
Externally publishedYes

Fingerprint

Stomach
Adenocarcinoma
Biomarkers
Recurrence
Messenger RNA
Stomach Neoplasms
Neoplasms
Reverse Transcription
Multivariate Analysis
Immunohistochemistry
Proteins

All Science Journal Classification (ASJC) codes

  • Surgery
  • Oncology

Cite this

Moon, J. H., Fujiwara, Y., Nakamura, Y., Okada, K., Hanada, H., Sakakura, C., ... Doki, Y. (2012). REGIV as a potential biomarker for peritoneal dissemination in gastric adenocarcinoma. Journal of Surgical Oncology, 105(2), 189-194. https://doi.org/10.1002/jso.22021

REGIV as a potential biomarker for peritoneal dissemination in gastric adenocarcinoma. / Moon, Jeong Ho; Fujiwara, Yoshiyuki; Nakamura, Yurika; Okada, Kaoru; Hanada, Hiroyuki; Sakakura, Chohei; Takiguchi, Shuji; Nakajima, Kiyokazu; Miyata, Hiroshi; Yamasaki, Makoto; Kurokawa, Yukinori; Mori, Masaki; Doki, Yuichiro.

In: Journal of Surgical Oncology, Vol. 105, No. 2, 01.02.2012, p. 189-194.

Research output: Contribution to journalArticle

Moon, JH, Fujiwara, Y, Nakamura, Y, Okada, K, Hanada, H, Sakakura, C, Takiguchi, S, Nakajima, K, Miyata, H, Yamasaki, M, Kurokawa, Y, Mori, M & Doki, Y 2012, 'REGIV as a potential biomarker for peritoneal dissemination in gastric adenocarcinoma', Journal of Surgical Oncology, vol. 105, no. 2, pp. 189-194. https://doi.org/10.1002/jso.22021
Moon JH, Fujiwara Y, Nakamura Y, Okada K, Hanada H, Sakakura C et al. REGIV as a potential biomarker for peritoneal dissemination in gastric adenocarcinoma. Journal of Surgical Oncology. 2012 Feb 1;105(2):189-194. https://doi.org/10.1002/jso.22021
Moon, Jeong Ho ; Fujiwara, Yoshiyuki ; Nakamura, Yurika ; Okada, Kaoru ; Hanada, Hiroyuki ; Sakakura, Chohei ; Takiguchi, Shuji ; Nakajima, Kiyokazu ; Miyata, Hiroshi ; Yamasaki, Makoto ; Kurokawa, Yukinori ; Mori, Masaki ; Doki, Yuichiro. / REGIV as a potential biomarker for peritoneal dissemination in gastric adenocarcinoma. In: Journal of Surgical Oncology. 2012 ; Vol. 105, No. 2. pp. 189-194.
@article{0e2732ba2e6643aba85448914fc183a9,
title = "REGIV as a potential biomarker for peritoneal dissemination in gastric adenocarcinoma",
abstract = "Background This study examined the clinical significance of regenerating islet-derived family member 4 (REGIV) in surgically resected gastric tumors. The potential of REGIV as a biomarker in gastric cancer was also assessed including its predictive value for prognosis and recurrence after surgery. Methods Immunohistochemistry was performed to assess the clinical significance of REGIV expression status in surgically resected specimens. The quantitative genetic diagnostic method, transcription-reverse transcription concerted reaction (TRC) that targeted REGIV mRNA was applied for prediction of peritoneal recurrence in gastric cancer. Results Positive immunostaining for REGIV was observed in 85 cases (52.5{\%}), and correlated significantly with diffuse type histopathology (P = 0.001), advanced T stage (P = 0.022), and frequent peritoneal recurrence (P = 0.009). Multivariate analysis identified advanced T stage (P < 0.001) and REGIV expression (P = 0.034) as independent prognostic factors for peritoneal recurrence-free survival. Overexpression of REGIV protein was evident in the majority of peritoneal tumors (93.8{\%}). REGIV mRNA assessed by TRC could be a predictive marker for peritoneal recurrence after curative operation. Conclusions REGIV overexpression is common in primary gastric tumors and a potentially suitable marker of diffuse type histopathology and peritoneal dissemination. Overexpression of REGIV mRNA, assessed by the TRC method, is a potentially suitable marker of peritoneal recurrence after curative resection.",
author = "Moon, {Jeong Ho} and Yoshiyuki Fujiwara and Yurika Nakamura and Kaoru Okada and Hiroyuki Hanada and Chohei Sakakura and Shuji Takiguchi and Kiyokazu Nakajima and Hiroshi Miyata and Makoto Yamasaki and Yukinori Kurokawa and Masaki Mori and Yuichiro Doki",
year = "2012",
month = "2",
day = "1",
doi = "10.1002/jso.22021",
language = "English",
volume = "105",
pages = "189--194",
journal = "Journal of Surgical Oncology",
issn = "0022-4790",
publisher = "Wiley-Liss Inc.",
number = "2",

}

TY - JOUR

T1 - REGIV as a potential biomarker for peritoneal dissemination in gastric adenocarcinoma

AU - Moon, Jeong Ho

AU - Fujiwara, Yoshiyuki

AU - Nakamura, Yurika

AU - Okada, Kaoru

AU - Hanada, Hiroyuki

AU - Sakakura, Chohei

AU - Takiguchi, Shuji

AU - Nakajima, Kiyokazu

AU - Miyata, Hiroshi

AU - Yamasaki, Makoto

AU - Kurokawa, Yukinori

AU - Mori, Masaki

AU - Doki, Yuichiro

PY - 2012/2/1

Y1 - 2012/2/1

N2 - Background This study examined the clinical significance of regenerating islet-derived family member 4 (REGIV) in surgically resected gastric tumors. The potential of REGIV as a biomarker in gastric cancer was also assessed including its predictive value for prognosis and recurrence after surgery. Methods Immunohistochemistry was performed to assess the clinical significance of REGIV expression status in surgically resected specimens. The quantitative genetic diagnostic method, transcription-reverse transcription concerted reaction (TRC) that targeted REGIV mRNA was applied for prediction of peritoneal recurrence in gastric cancer. Results Positive immunostaining for REGIV was observed in 85 cases (52.5%), and correlated significantly with diffuse type histopathology (P = 0.001), advanced T stage (P = 0.022), and frequent peritoneal recurrence (P = 0.009). Multivariate analysis identified advanced T stage (P < 0.001) and REGIV expression (P = 0.034) as independent prognostic factors for peritoneal recurrence-free survival. Overexpression of REGIV protein was evident in the majority of peritoneal tumors (93.8%). REGIV mRNA assessed by TRC could be a predictive marker for peritoneal recurrence after curative operation. Conclusions REGIV overexpression is common in primary gastric tumors and a potentially suitable marker of diffuse type histopathology and peritoneal dissemination. Overexpression of REGIV mRNA, assessed by the TRC method, is a potentially suitable marker of peritoneal recurrence after curative resection.

AB - Background This study examined the clinical significance of regenerating islet-derived family member 4 (REGIV) in surgically resected gastric tumors. The potential of REGIV as a biomarker in gastric cancer was also assessed including its predictive value for prognosis and recurrence after surgery. Methods Immunohistochemistry was performed to assess the clinical significance of REGIV expression status in surgically resected specimens. The quantitative genetic diagnostic method, transcription-reverse transcription concerted reaction (TRC) that targeted REGIV mRNA was applied for prediction of peritoneal recurrence in gastric cancer. Results Positive immunostaining for REGIV was observed in 85 cases (52.5%), and correlated significantly with diffuse type histopathology (P = 0.001), advanced T stage (P = 0.022), and frequent peritoneal recurrence (P = 0.009). Multivariate analysis identified advanced T stage (P < 0.001) and REGIV expression (P = 0.034) as independent prognostic factors for peritoneal recurrence-free survival. Overexpression of REGIV protein was evident in the majority of peritoneal tumors (93.8%). REGIV mRNA assessed by TRC could be a predictive marker for peritoneal recurrence after curative operation. Conclusions REGIV overexpression is common in primary gastric tumors and a potentially suitable marker of diffuse type histopathology and peritoneal dissemination. Overexpression of REGIV mRNA, assessed by the TRC method, is a potentially suitable marker of peritoneal recurrence after curative resection.

UR - http://www.scopus.com/inward/record.url?scp=84855353428&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84855353428&partnerID=8YFLogxK

U2 - 10.1002/jso.22021

DO - 10.1002/jso.22021

M3 - Article

C2 - 21780125

AN - SCOPUS:84855353428

VL - 105

SP - 189

EP - 194

JO - Journal of Surgical Oncology

JF - Journal of Surgical Oncology

SN - 0022-4790

IS - 2

ER -